Navigation Links
Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease
Date:6/11/2009

About Dimebon

Dimebon is an investigational compound currently in Phase 3 development for the treatment of Alzheimer's disease and in clinical development for Huntington disease. In preclinical models of Alzheimer's disease and Huntington disease explored thus far, dimebon has been shown to inhibit brain cell death, potentially by stabilizing and improving mitochondrial function in a way that prevents neuron death and dysfunction. The dimebon mechanism is thought to be distinct from that of currently available Alzheimer's disease medications.

In addition to CONNECTION, dimebon is being studied in the 12-month Phase 3 CONCERT trial, which is evaluating the efficacy of dimebon when added to ongoing treatment with donepezil (Aricept(R)) in patients with mild-to-moderate Alzheimer's disease, and in a Phase 3 safety study. Two Phase 3 studies in moderate-to-severe Alzheimer's disease are also planned to start this year.

In Huntington disease, a Phase 2 study has been completed. Medivation and Pfizer expect to initiate a Phase 3 trial this year to evaluate the potential benefits of dimebon on cognition in patients with Huntington disease.

About Alzheimer's Disease

Alzheimer's disease is a progressive degenerative brain disorder that gradually destroys a person's memory and ability to learn, reason, make judgments, communicate and carry out daily activities. As the disease progresses, patients may experience changes in personality and behavior, such as anxiety, suspiciousness or agitation, as well as delusions or hallucinations.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medivation Announces Pricing of Public Offering
2. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
3. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
4. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
5. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
6. Medivation Presents New Data on Dimebons Novel Mechanism of Action
7. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
8. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
9. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
10. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
11. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... , Oct. 19, 2014 NextCODE Health, which ... whole genome in real time, today announced the launch of ... NextCODE Exchange , at the American Society of Human Genetics ... To learn more, sign up and apply for free beta ... unique features and benefits can be viewed here . ...
(Date:10/19/2014)... The Asian Orthopedic braces and support systems ... analysis and forecast of revenue. The Orthopedic braces and support ... $416.5 million by 2018, at a developing CAGR of 4.4% ... the Asian Orthopedic braces and support systems market, to get ... a glimpse of the segmentation of orthopedic braces and support ...
(Date:10/18/2014)... The report "1,6-Hexanediol Market by Application and ... analyzes the global market on the basis of ... details such as the key drivers, current trends ... Browse 81 Market Data Tables and 29 Figures ... “1,6-Hexanediol Market by Application and by Geography - ...
(Date:10/18/2014)... 2014 The Biomass Power ... five years to 2014. The industry's expansion has been ... credits that encouraged the use of biomass power. Furthermore, ... (RPSs), which require local utilities to generate electricity from ... portfolio. Increased campaigning for green technology also influenced industry ...
Breaking Biology Technology:The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 21,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 31,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 5Biomass Power in the US Industry Market Research Report from IBISWorld Has Been Updated 2Biomass Power in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... FREISING-WEIHENSTEPHAN, Germany, September 5 Pieris AG,a ... of,targeted human protein therapeutics, today announced successful ... the use of Anticalins(R) in,ophthalmologic disease. ... PRS-055, an Anticalin(R),specific for VEGF. VEGF is ...
... in over 60% of evaluable patients -, SEOUL, ... ) today reported interim data from an ongoing phase ... non-small cell,lung cancer (NSCLC). This open-label phase 2 trial ... IV NSCLC who have adenocarcinoma,histology and meet one of ...
... at Houston,s Rice University and electronics specialists at ... formation of a $2.6-million Institute for Sustainable Nanoelectronics ... million Singapore dollars, aims to slash the design ... computer chips that power everything from cell phones ...
Cached Biology Technology:Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer 2Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer 3Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer 4Rice, Nanyang Tech collaborate on sustainable nanoelectronics 2Rice, Nanyang Tech collaborate on sustainable nanoelectronics 3
(Date:10/15/2014)... has admitted Johannes Gutenberg University Mainz (JGU) as ... hub continues to maintain a significant nationwide standing ... "The acceptance of Johannes Gutenberg University Mainz as ... milestone in the national and international competition for ... of Rhineland-Palatinate can be proud that Mainz University ...
(Date:10/15/2014)... will be awarded the 44th Rosenstiel Award for Distinguished ... pioneering research exploring the mechanisms of genomic instability and ... Alt is the second alumnus to win the Rosenstiel ... in 2003. , Alt is the Charles A. Janeway ... Medical School and an investigator at the Howard Hughes ...
(Date:10/14/2014)... of years since T. rex took its ... scientists is breathing life back into dinosaurs using high-powered ... research has important implications for how dinosaurs used their ... sense of smell and cool their brains. , ... student Jason Bourke, lead author of the new study ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... that exposure to low to moderate amounts of arsenic ... about 120 parts per billion of arsenic in well ... damage comparable to decades of smoking tobacco. Smoking, especially ... is the first population-based study to clearly demonstrate significant ...
... fetal dermal cells (MFDCs) may be an ideal source ... Their performance is superior to that of adult dermal ... a cell isolation technique for MFDCs and subsequently published ... the journal Cell Transplantation , and is now ...
... Putnam Valley, NY. (Aug. 22, 2013) Patients ... find the treatment life-saving, but often suffer progressive ... memory deficits. The cognitive deficits are a contributing ... the surviving patients, quality of life after radiation ...
Cached Biology News:Study adds lung damage to harmful effects of arsenic 2Study adds lung damage to harmful effects of arsenic 3Study adds lung damage to harmful effects of arsenic 4Fetal tissue-derived stem cells may be ideal source for repairing tissues and organs 2Fetal stem cell transplantation favorably impacts radiation-induced cognitive dysfunction 2
Applications: Western blotting ...
... of positioning slides offers multiple drive ... micrometer, and manual. With this series, ... multi-axis systems. These slides also offer ... down to 10 nanometers, integrated home/ ...
...
... for relax positively and negatively supercoiled DNA in ... , Studying the effects of supercoiling on transcription ... vitro , Determining the degree of supercoiling ... plasmids that differ in length by only one ...
Biology Products: